Sentinel Lymph Node Mapping in Esophageal Cancer Using ICG Dye and NIR Imaging

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · May 20, 2020

Keywords

ClinConnect Summary

This clinical trial is studying a new method called sentinel lymph node mapping using a special dye (ICG) and imaging technology (NIR) to help doctors find out if esophageal cancer has spread to nearby lymph nodes. The goal is to see if this method can be used effectively in patients with esophageal or esophagogastric junction cancer. If successful, this approach could allow surgeons to only remove the important lymph nodes (the sentinel nodes) instead of taking out all lymph nodes, which is the current practice.

To be eligible for this trial, participants need to be at least 18 years old and have a specific type of esophageal cancer called adenocarcinoma that is located in the lower part of the esophagus or at the esophagogastric junction. They must also be planning to have a minimally invasive surgery to remove the cancer. However, people who are allergic to iodide or seafood, those with certain health conditions, or those who have advanced cancer that has spread too far may not qualify. If you decide to participate, you will be involved in the study before your surgery and will need to provide informed consent, which means you will understand and agree to the study's procedures.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pathological diagnosis of adenocarcinoma tumor located in distal 1/3 of esophagus or esophagogastric junction , with a plan to undergo minimally invasive esophagectomy.
• • All patients with Stage IVA (AJCC Cancer Staging Manual, 8th edition) disease will be eligible
• • ≥18 years of age.
• • Documented, signed, and dated informed consent, obtained before any procedures, for the proposed research study and for standard surgical resection.
• Exclusion Criteria:
• • No plan to undergo surgical resection.
• • Severe iodide or seafood allergy.
• • Women of childbearing potential without a negative pregnancy test; or women who are lactating.
• • Prior diagnosis of severe hepatic or renal dysfunction.
• • Patients with Stage IVB or M1 disease (AJCC Cancer Staging Manual, 8th edition)
• • Patients with local recurrence and planning to undergo salvage esophagectomy